Bayer has completed the acquisition of Perfuse Therapeutics, fully absorbing the company and securing complete rights to its lead asset, PER-001 intravitreal implant. 

 

The deal strengthens Bayer’s push deeper into ophthalmology, a core strategic area for the pharma giant.

 

PER-001 is a first-in-class, sustained-release small molecule endothelin receptor antagonist currently in Phase II development for the treatment of Glaucoma and Diabetic Retinopathy (DR), positioning it as a potentially important addition to Bayer’s eye-care pipeline.

 

“This acquisition strengthens Bayer’s pharmaceutical pipeline and strategically fits with Bayer’s strong footprint and expertise in ophthalmology.”

 

Financially, Bayer paid an upfront USD 300 million for Perfuse. The transaction could reach a total value of up to USD 2.45 billion, including milestone-based payments tied to future development and regulatory success.

 

Advisory roles on the deal included BofA Securities as exclusive financial advisor to Bayer, with Baker McKenzie serving as legal counsel. For Perfuse, Centerview Partners LLC acted as exclusive financial advisor, and Goodwin Procter LLP served as legal counsel.